Vascepa is a prescription medication that contains the active ingredient icosapent ethyl, which is used to reduce the risk of cardiovascular events in certain patients. It is manufactured by Amarin Pharma, and its patent was recently upheld in a court appeal [2]. The patent protection for Vascepa is set to expire in 2030 [1]. In comparison, generic versions of icosapent ethyl are not yet available on the market.
One of the benefits of Vascepa over generics is that it has been extensively studied in clinical trials. In fact, the FDA has approved Vascepa based on the results of a large-scale clinical trial that demonstrated its efficacy in reducing cardiovascular events [3]. This trial showed that Vascepa reduced the risk of cardiovascular events by 25% compared to placebo [3]. The FDA has not yet approved any generic versions of icosapent ethyl, so there is no data available on their efficacy.
Another benefit of Vascepa is that it is specifically indicated for patients with elevated triglyceride levels. Triglycerides are a type of fat found in the blood, and high levels are a risk factor for cardiovascular disease [3]. Vascepa has been shown to be effective in reducing triglyceride levels, which can help to reduce the risk of cardiovascular events [3]. Generic versions of icosapent ethyl may not be specifically indicated for this patient population.
In conclusion, while generic versions of icosapent ethyl are not yet available on the market, there are several benefits to using Vascepa over generics. Vascepa has been extensively studied in clinical trials and has been shown to be effective in reducing the risk of cardiovascular events in patients with elevated triglyceride levels. Additionally, Vascepa is specifically indicated for this patient population, while generic versions may not be.
Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.fiercepharma.com/marketing/it-s-confirmed-amarin-loses-patent-appeal-protecting-blockbuster-hopeful-vascepa-from
[3] https://www.vascepahcp.com/resources/pharmacists/